10x Genomics Inc(TXG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.59 | Insider Own | 10.93% | Shs Outstand | 120.2M | Perf Week | 7.72% |
| Market Cap | 8.65B | Forward P/E | - | EPS next Y | 3.44% | Insider Trans | -1.53% | Shs Float | 116.0M | Perf Month | 13.56% |
| Enterprise Value | 8.18B | PEG | - | EPS next Q | -0.26 | Inst Own | 105.67% | Short Float | 13.72% | Perf Quarter | 128.13% |
| Income | -0.08B | P/S | 14.03 | EPS this Y | -108.97% | Inst Trans | 3.48% | Short Ratio | 5.09 | Perf Half Y | 224.58% |
| Sales | 0.62B | P/B | 10.48 | EPS next 5Y | -5.8% | ROA | -7.47% | Short Interest | 15.93M | Perf YTD | 307.17% |
| Book/sh | 6.34 | P/C | 15.67 | EPS past 3/5Y | 37.9% 42.1% | ROE | -9.4% | 52W High | -1.79% ($67.62) | Perf Year | 427.48% |
| Cash/sh | 4.24 | P/FCF | 71.25 | Sales past 3/5Y | 7.57% 16.55% | ROIC | -8.42% | 52W Low | 495.07% ($11.16) | Perf 3Y | 40.22% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.82% | Gross Margin | 70.58% | Volatility(W/M) | 6.18% 5.93% | Perf 5Y | -64.01% |
| Dividend TTM | - | EV/Sales | 13.26 | Sales Y/Y TTM | -4.28% | Oper. Margin | -14.12% | ATR (14) | 3.67 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.25 | EPS Q/Q | -149.75% | Profit Margin | -12.18% | RSI (14) | 65.35 | Recom | 2.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.69 | Sales Q/Q | -12.65% | SMA20 | 6.47% ($62.37) | Beta | 2.04 | Target Price | $52.13 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/8/6 | SMA50 | 26.22% ($52.61) | Rel Volume | 0.78 | Prev Close | $67.29 |
| Employees | 1178 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 42.41% 2.97% | SMA200 | 123.63% ($29.7) | Avg Volume(3M) | 3.13M | Price | $66.41 |
| IPO | 2019/9/12 | Option/Short | Yes/Yes | Trades | 23475 | Volume | 2,428,064 | Change | -1.31% |
Company
TXG is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A life sciences technology company that provides tools for single-cell and spatial genomics analysis. It supplies instruments, consumables, and software for single-cell and spatial biology research, which are used by research institutions and pharmaceutical companies for precision biology studies. A leading company in the single-cell and spatial analysis field.
Over the past 1 year, on the higher side
2% below its 1-year high.
TXG has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -109.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +40.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 105.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ARKG 0.06%
GNOM 0.03%
PINK 0.03%
FMED 0.03%
AUMI 0.03%It ranks #4 in the industry
Based on market cap of $9B.
TXG $9B PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is TXG?
TXG belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TXG?
The market cap of TXG is approximately $8.7B, ranking 1,033 within its sector.
What is the 52-week high and low for TXG?
TXG has recorded a 52-week high of $67.62 and a low of $11.16.
